1. Scrip
  2. >>Therapy Areas

Mixed Early Phase III Results With Aldeyra’s First-In-Class Dry Eye Candidate

Aldeyra To Initiate Part 2 Of The Adaptive Phase III Study In 2020

 
• By John Davis

The first part of Aldeyra’s Phase III RENEW study of the aldehyde trap candidate, reproxalap, shows positive effects on one of two co-primary endpoints and indicates an induction-maintenance dosing regimen should be used in part 2 of the study, expected to start in the first half of next year.

Red_Eye
• Source: Shutterstock

Aldeyra Therapeutics Inc. has presented mixed top-line results from part 1 of its adaptive Phase III RENEW study of the potential first-in-class dry eye disease therapy, reproxalap, and investors have reacted cautiously to the data.

The Lexington, MA-based biotech’s share price on NASDAQ declined by 32% on 3 December to $5.06, the day the data...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

More from Therapy Areas

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 
• By Jessica Merrill

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.